| A systematic review of neurological symptoms and complications of COVID-19 X Chen, S Laurent, OA Onur, NN Kleineberg, GR Fink, F Schweitzer, ... Journal of neurology 268, 392-402, 2021 | 327 | 2021 |
| l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients N Schwab, T Schneider-Hohendorf, V Posevitz, J Breuer, K Göbel, ... Neurology 81 (10), 865-871, 2013 | 169 | 2013 |
| Immunological aspects of approved MS therapeutics PS Rommer, R Milo, MH Han, S Satyanarayan, J Sellner, L Hauer, Z Illes, ... Frontiers in immunology 10, 1564, 2019 | 149 | 2019 |
| Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? C Warnke, T Menge, HP Hartung, MK Racke, PD Cravens, JL Bennett, ... Archives of neurology 67 (8), 923-930, 2010 | 149 | 2010 |
| Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation TFM Andlauer, D Buck, G Antony, A Bayas, L Bechmann, A Berthele, ... Science advances 2 (6), e1501678, 2016 | 148 | 2016 |
| The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability F Henkler, E Behrle, KM Dennehy, A Wicovsky, N Peters, C Warnke, ... The Journal of cell biology 168 (7), 1087-1098, 2005 | 146 | 2005 |
| Low-frequency and rare-coding variation contributes to multiple sclerosis risk M Mitrovič, NA Patsopoulos, AH Beecham, T Dankowski, A Goris, ... Cell 175 (6), 1679-1687. e7, 2018 | 132 | 2018 |
| Review of teriflunomide and its potential in the treatment of multiple sclerosis C Warnke, G Meyer zu Hörste, HP Hartung, O Stüve, BC Kieseier Neuropsychiatric disease and treatment, 333-340, 2009 | 108 | 2009 |
| Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy M Stettner, L Hinrichs, R Guthoff, S Bairov, IN Petropoulos, C Warnke, ... Annals of clinical and translational neurology 3 (2), 88-100, 2016 | 100 | 2016 |
| Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy C Warnke, G von Geldern, P Markwerth, T Dehmel, R Hoepner, R Gold, ... Annals of neurology 76 (6), 792-801, 2014 | 100 | 2014 |
| Disease-modifying agents for multiple sclerosis: recent advances and future prospects T Menge, MS Weber, B Hemmer, BC Kieseier, HC von Büdingen, ... Drugs 68, 2445-2468, 2008 | 100 | 2008 |
| Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety D Dubey, BC Kieseier, HP Hartung, B Hemmer, C Warnke, T Menge, ... Expert review of neurotherapeutics 15 (4), 339-346, 2015 | 92 | 2015 |
| Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis S Abrahamyan, B Eberspächer, MM Hoshi, L Aly, F Luessi, S Groppa, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (7), 681-686, 2020 | 89 | 2020 |
| Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis F Schweitzer, S Laurent, GR Fink, MH Barnett, S Reddel, HP Hartung, ... Current opinion in neurology 32 (3), 305-312, 2019 | 81 | 2019 |
| Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF C Warnke, M Stettner, V Lehmensiek, T Dehmel, AK Mausberg, ... Multiple Sclerosis Journal 21 (8), 1036-1044, 2015 | 80 | 2015 |
| Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19 L Rolfes, M Pawlitzki, S Pfeuffer, C Nelke, A Lux, R Pul, C Kleinschnitz, ... Neurology: Neuroimmunology & Neuroinflammation 8 (5), e1035, 2021 | 76 | 2021 |
| Changes to anti-JCV antibody levels in a Swedish national MS cohort C Warnke, R Ramanujam, T Plavina, T Bergström, S Goelz, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1199-1205, 2013 | 76 | 2013 |
| Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases RP Maas, AHG Muller-Hansma, RAJ Esselink, JL Murk, C Warnke, ... Journal of Neurology 263, 2004-2021, 2016 | 75 | 2016 |
| Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity VI Leussink, L Husseini, C Warnke, E Broussalis, HP Hartung, ... Therapeutic Advances in Neurological Disorders 5 (5), 255-266, 2012 | 75 | 2012 |
| Recovery of the T-cell repertoire in CIDP by IV immunoglobulins AK Mausberg, M Dorok, M Stettner, M Müller, HP Hartung, T Dehmel, ... Neurology 80 (3), 296-303, 2013 | 69 | 2013 |
